Texila International Journal of Academic Research
ISSN: 2520-3088
DOI: 10.21522/TIJAR.2014.12.02.Art018

From Prevention to Intervention: Advanced Cholesterol-Lowering Techniques in Cardiovascular and Coronary Care – A Systematic Review

Faraaz Zaveri[1*], Saria Naser[2]
[1]*Department of Cardiology, Texila American University, Nicaragua*
[2]*Department of General Medicine, Soochow University, China*

Abstract

Dyslipidemia, marked by elevated low-density lipoprotein cholesterol (LDL-C), is a key contributor to atherosclerotic cardiovascular disease (ASCVD) and remains a global health challenge. Advances in lipid management have transitioned from statin monotherapy to combination therapies with ezetimibe and PCSK9 inhibitors, achieving LDL-C reductions of up to 85% and significantly lowering major adverse cardiovascular events (MACE). Emerging agents, including bempedoic acid and RNA-directed therapies such as inclisiran and antisense oligonucleotides targeting lipoprotein(a), offer alternative solutions for statin-intolerant populations and those with residual cardiovascular risk. Intracoronary imaging demonstrates the benefits of aggressive LDL-C lowering on plaque regression and stabilization, reinforcing the importance of early initiation and sustained control. Simplified regimens, such as single-pill combinations, improve adherence and address barriers like cost and access, essential for maximizing therapeutic outcomes. Additionally, tools such as coronary artery calcium (CAC) scoring and advanced imaging enable personalized care and refined risk stratification. This meta-analysis synthesizes evidence to highlight a paradigm shift towards aggressive, individualized lipid management strategies that bridge gaps between clinical trials and real-world practice. By integrating pharmacological innovations with lifestyle interventions, these advancements offer transformative potential to reduce ASCVD risk globally.

Keywords: *Atherosclerotic cardiovascular Disease, Combination Therapies, Dyslipidemia, LDL Cholesterol, Lipid-Lowering Therapies, PCSK9 Inhibitors.*

Introduction

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide, driven by elevated levels of low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins such as lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins. The direct relationship between LDL-C levels and the progression of ASCVD underscores its critical role as a therapeutic target. Despite decades of reliance on statins as the cornerstone of lipid management, many patients, particularly those at high or very high cardiovascular risk, fail to achieve guideline-recommended LDL-C goals. This persistent gap highlights the need for advanced therapeutic strategies that integrate emerging non-statin agents.

Modern lipid-lowering therapies have expanded beyond statins to include ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and bempedoic acid, offering novel mechanisms of action and enhanced LDL-C reductions. RNA-directed therapies such as inclisiran, and antisense oligonucleotides targeting Lp(a), exemplify recent innovations, providing effective, long-lasting options for managing dyslipidemia. Evidence from landmark trials such as FOURIER, ODYSSEY, CLEAR Outcomes,

Received: 12.02.2025 ***Accepted: 18.04.2025*** ***Published on: 30.04.2025***
****Corresponding Author: drfaraazzaveri@outlook.com***

and findings from the DA VINCI study highlight the potential of combination therapies, which achieve LDL-C reductions exceeding 85% and substantial decreases in major adverse cardiovascular events (MACE) and cardiovascular mortality [2, 11].

Aggressive LDL-C lowering has become a pivotal goal in both primary and secondary prevention of ASCVD. Recent European and American guidelines emphasize early initiation and sustained reductions in LDL-C, with targets set at <55 mg/dL for very high-risk patients and <70 mg/dL for high-risk populations. Additionally, achieving non-high-density lipoprotein cholesterol (non-HDL-C) goals has proven crucial, particularly following acute coronary syndromes (ACS). Registry-based studies, such as SWEDEHEART, and cross-sectional findings from the DA VINCI study have reinforced the importance of rapid and sustained lipid lowering. These studies demonstrate not only the benefits of achieving guideline-recommended LDL-C targets but also highlight regional disparities in adherence to lipid-lowering strategies, underscoring the need for standardized approaches across healthcare systems [11].

Incorporating advanced lipid-lowering strategies into clinical practice has redefined ASCVD management. High-intensity statins remain foundational, but the addition of ezetimibe and PCSK9 inhibitors, either as part of stepwise intensification or in fixed-dose combinations, significantly improves LDL-C goal attainment. The DA VINCI study confirms that combination therapies, particularly those involving PCSK9 inhibitors, provide superior LDL-C reductions compared to monotherapy, though their adoption remains limited due to cost and accessibility barriers [11]. Emerging therapies such as bempedoic acid and inclisiran provide effective alternatives for statin-intolerant patients, broadening the therapeutic arsenal for dyslipidemia management [2, 11].

The interplay between pharmacological advancements and lifestyle interventions also remains essential. Dietary modifications, such as adherence to the Mediterranean or DASH diet, regular physical activity, and smoking cessation, further reduce ASCVD risk and complement pharmacotherapy. Integration of non-statin agents has proven particularly effective in high-risk groups, including those with familial hypercholesterolemia, diabetes, or chronic kidney disease, where statins alone are often insufficient. Additionally, the use of intracoronary imaging has illuminated the role of lipid-lowering therapies in plaque regression and stabilization, providing further evidence for their integration into clinical practice [2].

Despite these advancements, barriers such as cost, accessibility, and adherence continue to hinder the widespread adoption of novel therapies. Simplified treatment regimens, such as single-pill combinations, and improved patient education represent practical solutions to enhance compliance and outcomes. Ongoing research focusing on long-term safety, real-world efficacy, and innovative approaches like gene-editing technologies offers promising avenues for the future of lipid management. Furthermore, addressing disparities in LDL-C goal attainment across regions, as highlighted by the DA VINCI study, is crucial for achieving equitable cardiovascular care [2].

This meta-analysis aims to synthesize the current evidence on advanced cholesterol-lowering techniques, highlighting their mechanisms of action, efficacy, safety profiles, and impact on cardiovascular outcomes. By bridging gaps between guideline recommendations and real-world practice, it seeks to provide a comprehensive framework for optimizing ASCVD prevention and management, addressing the unmet needs of diverse patient populations worldwide [2, 11].

Materials and Methods

Study Design

This meta-analysis synthesizes data from major studies and clinical guidelines focusing on advanced lipid-lowering therapies and their impact on cardiovascular and coronary care. The articles reviewed include randomized controlled trials (RCTs), systematic reviews, registry-based analyses, and population studies. Each study evaluated distinct aspects of lipid-lowering strategies, including mechanisms of action, efficacy, safety, patient stratification, and clinical outcomes. The DA VINCI study contributed insights into real-world LDL-C goal attainment across European countries, highlighting gaps in adherence to guidelines and regional variability in outcomes [11]. The primary objective was to integrate findings into a cohesive framework that informs the prevention and intervention strategies for dyslipidemia and ASCVD management.

Study Population

The study population in this meta-analysis encompasses a diverse group of patients across varying demographics and clinical contexts. High-risk populations include individuals with established atherosclerotic cardiovascular disease (ASCVD), those with familial hypercholesterolemia (FH), and diabetic patients with comorbid dyslipidemia. Moderate- and low-risk groups are also represented, including primary prevention cohorts with elevated LDL-C levels and intermediate-risk individuals identified through coronary artery calcium (CAC) scoring. Additionally, the analysis considers statin-intolerant populations who are unable to tolerate high- or moderate-intensity statins due to adverse effects. Regional variability is addressed through studies like the DA VINCI study, which assessed LDL-C goal attainment across 18 European countries, stratifying patients by cardiovascular risk using tools such as the SCORE2 and REACH calculators [11].

Study Population based on Risk Categories

Cardiovascular risk stratification involves assessing the likelihood of a person experiencing an atherosclerotic cardiovascular (CV) event within a specific timeframe. This evaluation considers the cumulative contribution of various CV risk factors. Some factors, like a history of previous atherosclerotic events, independently classify individuals as very high-risk, regardless of additional risk factors.

The guidelines emphasize systematic risk evaluations, particularly for individuals with chronic kidney disease, familial hypercholesterolemia, diabetes, or atherosclerotic cardiovascular disease (ASCVD). Risk classifications—moderate, high, or very high—help clinicians establish appropriate LDL cholesterol and blood pressure targets, enhancing therapeutic precision.

A significant addition is the concept of "lifetime risk," which predicts the age at which an individual has a 50% likelihood of developing a fatal or non-fatal cardiovascular event. This approach, combined with tools like the ESC CVD Risk Calculation app, enables personalized care and improves risk estimation by considering variables such as age, changes in risk factor levels, and other modifiers. [12, 13]. As shown in Table 1, risk categories are determined based on various clinical factors, allowing for targeted lipid-lowering interventions.

Table 1. Risk Stratification Categories

Age Group	Moderate–Low CV Risk	High CV Risk	Very High CV Risk
<50 years	<2.5%	2.5–7.5%	≥7.5%
50–69 years	<5%	5–10%	≥10%
≥70 years	<7.5%	7.5–15%	≥15%

Different guidelines, including those from the American Heart Association (AHA), American College of Cardiology (ACC), and the European Society of Cardiology (ESC), employ varying risk calculation methods. The AHA/ACC guidelines use pooled cohort equations (PCEs) to estimate a 10-year risk of non-fatal myocardial infarction, coronary artery disease death, or stroke in individuals without prior ASCVD. High-risk conditions encompass individuals aged 65 years or older, those with heterozygous familial hypercholesterolemia (HeFH), a history of coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) unrelated to a major ASCVD event, diabetes mellitus (DM), hypertension (HTN), chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) of 15–59 mL/min/1.73 m², active smoking, persistently elevated LDL-C levels of ≥100 mg/dL despite maximum tolerated doses of statins and ezetimibe, or a history of congestive heart failure (CHF).

The ESC guidelines categorize individuals into low-, intermediate-, high-, or very high-risk groups based on the presence of major risk factors or, in healthy individuals, a 10-year risk estimate using the SCORE2 or SCORE2-OP (Older Persons) models. These models account for regional variations and predict the risk of total CV events. For diabetic patients, stratification relies on ASCVD presence, severe target organ damage, or SCORE2-Diabetes. As seen in Table 2, therapeutic targets for LDL cholesterol are more stringent for high-risk individuals to minimize the risk of cardiovascular events.

Table 2. Therapeutic LDL Targets by Risk Category

Risk Category	LDL Cholesterol Target
Very High Risk	<1.4 mmol/L (<55 mg/dL); ≥50% reduction from baseline
Very High Risk (Recurrent Events)	<1 mmol/L (<40 mg/dL); in cases of a second event within 2 years can be considered
High Risk	<1.8 mmol/L (<70 mg/dL); ≥50% reduction from baseline
Moderate Risk	<2.6 mmol/L (<100 mg/dL)

Recent recommendations propose introducing an "extremely high-risk" category, encompassing patients with recurrent major CV events within two years, polyvascular disease, multivessel coronary artery disease, or recent acute coronary syndrome (ACS). This new classification enables clinicians to identify individuals who may benefit from intensified lipid-lowering therapies and stricter LDL-C targets. Figure 1 illustrates the recommended LDL-C targets based on cardiovascular risk categories, providing a clear framework for clinical decision-making.



Figure 1. LDL-C targets based on Cardiovascular Risk Categories

Risk modifiers such as family history of premature ASCVD, chronic inflammatory conditions, elevated lipoprotein(a), and non-zero coronary artery calcium scores may upgrade an individual's risk category, guiding more aggressive intervention strategies.

Lipid-Lowering Interventions

Effective lipid-lowering strategies form the cornerstone of cardiovascular risk reduction.

Statins

Statins such as Hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitors are the primary therapy for reducing cardiovascular burden. High-intensity statins reduced LDL-C by 50% (e.g., atorvastatin, rosuvastatin) [1, 3, 6]. Moderate-intensity statins achieved reductions of 30–40% [1, 3, 6]. However, non-statin treatments are increasingly utilized, either as alternatives or in combination with statins, particularly for individuals requiring additional LDL cholesterol (LDL-C) reduction or those intolerant to statins. [14].

Ezetimibe: Targeting Cholesterol Absorption

Ezetimibe reduces intestinal cholesterol absorption by inhibiting the Niemann-Pick C1-like 1 (NPC1L1) protein on the enterocyte brush border. As a monotherapy, ezetimibe achieves a 15–22% reduction in LDL-C levels and further enhances LDL-C reduction by an additional 21–27% when combined with statins. It modestly lowers triglycerides by 8% and increases HDL-C by 5%. The **IMPROVE-IT trial** demonstrated the clinical efficacy of ezetimibe when used alongside statins, showing significant cardiovascular event reductions [15, 16]. Ezetimibe is well-tolerated, though mild diarrhea or headache may occur. It is contraindicated in patients with moderate to severe liver impairment due to potential hepatic adverse effects.

Therapy Targeting PCSK9: Enhancing LDL Receptor Activity

PCSK9 inhibitors, such as alirocumab and evolocumab, are monoclonal antibodies that prevent PCSK9 from degrading LDL receptors, thereby increasing LDL clearance

from circulation [17]. These drugs, administered via subcutaneous injections, have been shown in trials like **ODYSSEY OUTCOMES** and **FOURIER** to reduce major adverse cardiovascular events (MACE) in high-risk individuals [18, 19]. Inclisiran, a small interfering RNA (siRNA) therapy, offers a unique mechanism by directly inhibiting PCSK9 production in hepatocytes, with biannual dosing schedules providing convenience [20, 21]. PCSK9 inhibitors demonstrate potent LDL-C reductions, with alirocumab and evolocumab reducing levels by 50–60%. Cost and injection-based administration remain barriers to widespread use, but their efficacy is particularly beneficial for individuals with severe dyslipidemia or statin intolerance.

Bempedoic Acid: An Oral Alternative

Bempedoic acid inhibits ATP citrate lyase, an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. This mechanism avoids muscle-related side effects, as bempedoic acid activation occurs only in the liver, not in skeletal muscle. Clinical trials, such as **CLEAR Harmony** and **CLEAR Wisdom**, have shown that bempedoic acid reduces LDL-C by approximately 18% and significantly decreases high-sensitivity C-reactive protein (hs-CRP) levels. The **CLEAR Outcomes trial** demonstrated a 21% reduction in cardiovascular events among patients treated with bempedoic acid [22, 23]. Common side effects include hyperuricemia, nasopharyngitis, and mild tendon disorders, making it an excellent option for individuals intolerant to statins.

Fibrates: Targeting Triglyceride Reduction

Fibrates activate peroxisome proliferator-activated receptor-alpha (PPARα), enhancing lipid metabolism and reducing very low-density lipoprotein (VLDL) production. Fenofibrate and gemfibrozil are the primary agents in this class, with fenofibrate showing promise in the **FIELD trial** for reducing diabetic retinopathy progression. While fibrates primarily lower triglycerides, they also slightly increase HDL-C and reduce LDL-C [24]. However, their use requires caution in patients with renal impairment, as fibrates are renally cleared and may pose a risk of nephrotoxicity.

Bile Acid Sequestrants: Disrupting Cholesterol Recycling

Bile acid sequestrants, such as cholestyramine, colestipol, and colesevelam, bind bile acids in the intestinal lumen, preventing their reabsorption. This forces the liver to utilize more cholesterol to produce bile acids, thereby reducing circulating LDL-C levels [25]. While these agents effectively lower LDL-C, their use is often limited by gastrointestinal side effects like bloating and constipation. Bile acid sequestrants are a suitable option for younger patients or pregnant women who cannot take statins or other systemic therapies.

Evinacumab: A Novel Approach for Severe Dyslipidemia

Evinacumab is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), which plays a key role in lipid metabolism. Unlike traditional LDL receptor-targeting therapies, evinacumab reduces LDL-C levels independently of LDL receptors. Approved for homozygous familial hypercholesterolemia (HoFH), evinacumab has demonstrated significant efficacy in trials such as the **ELIPSE HoFH trial**, achieving LDL-C reductions of over 47% [26]. Its unique mechanism makes it particularly valuable for individuals with severe or refractory dyslipidemia, though its high cost and limited availability restrict widespread use.

Lomitapide and Mipomersen: Specialized Therapies for Familial Hypercholesterolemia

Lomitapide inhibits microsomal triglyceride transfer protein (MTP), reducing the assembly of apoB-containing lipoproteins and significantly lowering LDL-C levels. However, its use is associated with hepatic steatosis and elevated liver enzymes, requiring close monitoring. Mipomersen, an antisense oligonucleotide targeting apoB-100 mRNA, reduces LDL-C by approximately 37% and is indicated for homozygous familial hypercholesterolemia [27]. Both therapies are reserved for patients with severe dyslipidemia who fail to achieve target LDL-C levels with conventional therapies. The **Homozygous FH studies** have validated their efficacy but highlighted their safety challenges.

LDL Apheresis: Extracorporeal Lipoprotein Removal

LDL apheresis is an extracorporeal treatment that selectively removes LDL-C and other apoB-containing lipoproteins from the bloodstream. This procedure achieves acute reductions in LDL-C by 50–60%, making it a crucial intervention for individuals with familial hypercholesterolemia unresponsive to pharmacologic therapies [28]. While effective, LDL apheresis is invasive and requires specialized equipment and trained personnel. Adverse events, such as transient hypotension, bleeding, or venous access complications, are potential drawbacks. The therapy is primarily reserved for patients with homozygous familial hypercholesterolemia or severe LDL-C elevations that cannot be managed through other treatments. Figure 2 compares the efficacy of statins, PCSK9 inhibitors, and other lipid-lowering agents, highlighting the superior effectiveness of combination therapies.



Figure 2. Effectiveness of Lipid-Lowering Therapies in LDL-C Reduction

Evaluating the Effectiveness of Lipid-Lowering Therapy

Both European and American guidelines emphasize the importance of monitoring the response to lipid-lowering therapies within a specific timeframe after initiation or adjustment. A follow-up assessment is recommended 4–12 weeks after the start of treatment to evaluate its effectiveness and make any necessary modifications. However, the recommended intervals for subsequent follow-ups differ between the two guidelines once the LDL-C target is achieved.

The European guidelines advise follow-up intervals of 6–12 months, whereas the American guidelines suggest a more variable timeframe of 3–12 months. In contrast, the ESC guidelines recommend shorter intervals of 4–6 weeks following an acute coronary syndrome (ACS). This is to ensure timely achievement of LDL-C goals during the critical early recovery period [13, 14]. Similarly, the writing committee advocates comparable shorter intervals for individuals at extreme risk to optimize care and minimize potential complications. Once stable, subsequent follow-ups every six months are advised for this high-risk group, with earlier evaluations recommended when dose adjustments are made.

During these follow-ups, a comprehensive lipid profile should be conducted, including assessments of non-HDL-C and ApoB, which serve as secondary treatment targets. Furthermore, adherence to prescribed medications and recommended lifestyle changes is vital for maximizing the benefits of lipid-lowering therapy and reducing the risk of ASCVD. Figure 3 presents an overview of risk categories, LDL-C targets, and the corresponding management strategies recommended by clinical guidelines.



Figure 3. Risk Categories, LDL-C Targets, and Corresponding Management Strategies

Outcome Measures

The primary outcome measures included several key aspects. The reduction in LDL-C percentages was a significant focus, with articles examining the effectiveness of various therapeutic regimens, including combination therapies, in achieving guideline-recommended LDL-C targets. Another critical measure was the reduction in major adverse cardiovascular events (MACE), such as myocardial infarction and cardiovascular death. Regional variability was also highlighted, with studies like the DA VINCI study showcasing differences in LDL-C goal attainment and healthcare access across European countries [11]. Additionally, the long-term safety profiles of novel therapies were assessed to ensure their viability for sustained use. Risk stratification was further enhanced through tools like coronary artery calcium (CAC) scoring and arterial imaging, refining patient management strategies.

Results

LDL-C Reduction Across Therapies

The meta-analysis highlights substantial progress in lipid-lowering strategies, with combination regimens demonstrating superior efficacy compared to monotherapies. High-intensity statins, such as atorvastatin and rosuvastatin, were shown to reduce LDL-C levels by approximately 50% [1, 3, 6]. Moderate-intensity statins achieved reductions in the range of 30–40% [1, 3, 6]. However, statin monotherapy often proved insufficient for high-risk populations to meet guideline-recommended LDL-C targets of <70 mg/dL for high-risk patients and <55 mg/dL for very-high-risk patients [2, 7, 11].

Combination therapies offered enhanced outcomes. Adding ezetimibe to statin therapy increased LDL-C reduction to approximately 65% [1, 5]. Incorporating PCSK9 inhibitors into combination regimens yielded even greater reductions, with LDL-C levels dropping by 75–85% [2, 4, 8]. Bempedoic acid, as a monotherapy, achieved an additional LDL-C reduction of around 18% and demonstrated increased efficacy when combined with statins or ezetimibe [5, 6, 11].

According to the ESC dyslipidemia guidelines, risk categories must adhere to the outlined recommendations. When additional LDL-C lowering of 20–30% is needed, particularly in non-acute settings, bempedoic acid may be added to the regimen. However, for more substantial LDL-C reductions required in very high- or extreme-risk cases, PCSK9-targeted therapies should be prioritized. While no large-scale studies directly compare PCSK9 inhibitors and bempedoic acid, both have been extensively evaluated across diverse risk profiles and shown to significantly reduce cardiovascular morbidity and mortality.

In resource-constrained environments, bempedoic acid offers a viable option for optimizing lipid control, although it is not yet included in standard guidelines. For elderly patients, those at risk of myopathy, individuals with CKD, or those with partial statin intolerance, initiating therapy with a moderate-intensity statin and ezetimibe is suggested. In cases of complete statin intolerance, a combination of ezetimibe and bempedoic acid may be employed, with the potential addition of PCSK9-targeted therapies depending on LDL-C levels achieved.

Novel Agents

Inclisiran, an siRNA-based therapy, has demonstrated an approximately 50% reduction in LDL-C levels while requiring fewer annual doses compared to traditional treatments [9, 2]. Additionally, antisense oligonucleotides targeting lipoprotein(a) have achieved reductions of up to 80% in Lp(a) levels, significantly lowering cardiovascular risk in patients with elevated Lp(a) levels [9, 10, 2].

LDL-C Goal Achievement

The percentage of patients achieving LDL-C targets increased with the intensification of therapy. Monotherapy with statins allowed only 25% of patients to reach LDL-C levels below 70 mg/dL [3, 7]. Adding ezetimibe to statin therapy improved this percentage to 45% [1, 5]. Further intensification with PCSK9 inhibitors resulted in over 75% of patients achieving LDL-C targets [2, 8].

Cardiovascular Outcomes

Combination therapies demonstrated significant benefits in improving cardiovascular outcomes. Statin monotherapy reduced major adverse cardiovascular events (MACE) by 15–20% [3, 6], while the addition of ezetimibe to statins enhanced MACE reduction to 25% [5]. Further intensification with the combination of statins, ezetimibe, and PCSK9 inhibitors achieved reductions of 30–35% [4, 8, 11]. In terms of mortality, PCSK9 inhibitors decreased cardiovascular mortality by 35% in high-risk populations [2, 4]. Intracoronary imaging studies also revealed greater regression and stabilization of atherosclerotic plaques with intensive therapies. Both PCSK9 inhibitors and inclisiran significantly contributed to the reduction of plaque burden [7, 9, 11].

Safety and Tolerability

Statins remain a cornerstone of lipid-lowering therapy, but their use is occasionally associated with adverse events such as myopathy and, in rare cases, rhabdomyolysis [1, 3]. Approximately 9% of patients experience statin intolerance, though complete intolerance is reported in less than 3% of cases [6]. PCSK9 inhibitors have been well-tolerated, with only mild injection-site reactions reported and no significant systemic side effects observed [2, 8]. Bempedoic acid has demonstrated minimal muscle-related side effects and reversible elevations in uric acid levels, making it a suitable alternative for statin-intolerant patients [5, 11]. Inclisiran and antisense therapies also showed favorable safety profiles, though rare cases of injection-site reactions and thrombocytopenia were reported in some clinical trials [9, 10, 11]. As illustrated in Table 3, different lipid-lowering regimens lead to varying degrees of cardiovascular risk reduction, emphasizing the need for personalized therapy.

Table 3. LDL-C Reduction and Cardiovascular Risk Reduction

Therapy Type	**LDL-C Reduction (%)**	**MACE Reduction (%)**	**Mortality Reduction (%)**
Statin Monotherapy	30–50	15–20	20
Statin + Ezetimibe	~65	25	28
Statin + PCSK9 Inhibitors	75–85	30–35	35
Bempedoic Acid	~18	21	—
Inclisiran	~50	—	—
Antisense Therapies (Lp(a))	~80 (Lp(a))	Significant	Significant

The impact of lipid-lowering therapies extends beyond LDL-C reduction to significantly lowering major adverse cardiovascular events (MACE) and cardiovascular mortality. Figure 4 presents a comparative analysis of various lipid-lowering therapies, demonstrating their combined effects on LDL-C levels, MACE reduction, and mortality outcomes.



Figure 4. Combined Reductions in LDL-C, MACE, and Mortality Across Various Lipid-Lowering Therapies.

Discussion

Summary of Findings

The findings from this study underscore the pivotal role of aggressive cholesterol-lowering strategies in managing atherosclerotic cardiovascular disease (ASCVD). Statins remain foundational for LDL-C reduction, achieving reductions of 30–50%. However, the consistent failure to meet guideline-recommended LDL-C targets in high-risk and very-high-risk populations necessitates combination therapies that integrate non-statin agents like ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran [1, 2, 3, 11]. These advanced therapies provide additive benefits, achieving LDL-C reductions of up to 85% and significantly lowering the risk of major adverse cardiovascular events (MACE) and cardiovascular mortality [4, 5, 8, 11]. Data from the DA VINCI study highlights significant gaps in LDL-C goal attainment, with fewer than 20% of very-high-risk patients achieving the recommended LDL-C target, further emphasizing the need for combination regimens and novel approaches [11].

Implications for Clinical Practice

Combination therapies, particularly those incorporating PCSK9 inhibitors, have demonstrated superior LDL-C reduction compared to statin monotherapy [3, 5, 9, 11]. Early and sustained LDL-C lowering following a myocardial infarction (MI) significantly reduces mortality and recurrent events. Additionally, reductions in non-HDL-C levels provide further prognostic value [10, 11]. Real-world evidence highlights the effectiveness of stepwise therapy intensification, with tailored regimens achieving LDL-C targets in up to 98% of patients [7, 11].

Novel agents also play an important role in contemporary lipid management. Inclisiran, with its biannual dosing schedule, offers a convenient and effective solution for patients who struggle with adherence to traditional therapies [6, 9, 11]. Antisense therapies targeting lipoprotein(a) (Lp(a)) address residual cardiovascular risk by reducing Lp(a) levels by up to 80% in high-risk cohorts [10, 11]. Bempedoic acid serves as a viable option

for statin-intolerant patients, combining a favorable safety profile with significant LDL-C reduction [2, 5, 7, 11].

Adjunctive lifestyle modifications, including the Mediterranean diet, regular physical activity, and smoking cessation, enhance the benefits of pharmacological therapies [2, 4, 6, 11]. Tools like coronary artery calcium (CAC) scoring further refine patient risk stratification, helping to guide therapy intensification for individuals in intermediate-risk categories [8, 10, 11].

Addressing Barriers to Implementation

Despite their demonstrated efficacy, the widespread adoption of advanced therapies is hindered by barriers such as cost, accessibility, and therapeutic inertia [3, 7, 11]. Findings from the DA VINCI study emphasize disparities in LDL-C goal attainment across European countries, reflecting regional differences in healthcare access and adherence to guideline-directed therapies [11]. Simplified regimens, including single-pill combinations, can improve adherence, while policy-level interventions are necessary to enhance affordability and availability of therapies like PCSK9 inhibitors and inclisiran [2, 6, 11].

Future Directions

The field of lipid management is on the cusp of significant advancements driven by innovation and precision medicine. Biomarker-driven approaches and genetic profiling are expected to play a pivotal role in tailoring therapies for conditions such as familial hypercholesterolemia (FH) and other high-risk populations, optimizing patient outcomes [8, 9, 11]. Additionally, the importance of real-world evidence cannot be overstated. Long-term studies are essential to validate the efficacy and safety of these therapies across diverse patient populations and clinical settings, ensuring their applicability and reliability [4, 7, 2].

A multidisciplinary approach will also remain central to achieving comprehensive cardiovascular risk reduction. The integration of pharmacological advancements with lifestyle interventions and patient education will be critical for sustained success in managing lipid levels and reducing cardiovascular risks [3, 5, 11].

Conclusion

The evolution of lipid-lowering strategies marks a transformative phase in the prevention and management of atherosclerotic cardiovascular disease (ASCVD). This analysis consolidates findings from pivotal studies to emphasize not only the efficacy of emerging therapies but also their necessity in addressing unmet needs within cardiovascular care. The persistent gap between guideline-directed LDL-C targets and real-world outcomes underscores the need for advanced, patient-centric strategies [1, 2, 11].

Advanced therapies such as ezetimibe, PCSK9 inhibitors, bempedoic acid, and RNA-based agents offer significant potential in achieving aggressive LDL-C targets. These treatments address key limitations of statins, including insufficient LDL-C reduction in high-risk populations and statin intolerance, while providing additional benefits such as lowering lipoprotein(a) [Lp(a)] and triglyceride-rich lipoproteins [3, 5, 9, 11]. Combination therapies, particularly those incorporating PCSK9 inhibitors and inclisiran, have demonstrated exceptional efficacy, with LDL-C reductions exceeding 85% and substantial reductions in major adverse cardiovascular events (MACE) and cardiovascular mortality among high- and very-high-risk patients [2, 4, 8].

Real-world evidence, including findings from studies like SWEDEHEART and DA VINCI, highlights the critical role of early and sustained LDL-C lowering in improving long-term cardiovascular outcomes. These studies emphasize the importance of initiating

aggressive lipid-lowering strategies early in the treatment process to maximize patient benefit [10, 11].

The adoption of combination regimens tailored to individual patient risk profiles is particularly beneficial for those with familial hypercholesterolemia, diabetes, or recurrent ASCVD events [2, 5, 11]. Additionally, the integration of non-statin agents offers a viable solution for statin-intolerant patients or individuals who fail to achieve LDL-C targets with conventional therapies. These approaches provide clinicians with flexible strategies to optimize lipid management in diverse patient populations [7, 8, 11].

The next frontier in lipid management lies in precision medicine, integrating genetic profiling and biomarker-driven approaches to tailor therapies for individual patients. Advanced imaging and risk stratification tools, such as coronary artery calcium (CAC) scoring, further refine treatment decisions and enable personalized care [4, 8, 2]. A multidisciplinary approach that combines pharmacological advancements with lifestyle interventions, as well as the development of simplified regimens like single-pill combinations, remains critical for comprehensive cardiovascular care [3, 6, 11].

This analysis affirms that advanced cholesterol-lowering therapies, when applied strategically, have the potential to significantly reduce the burden of ASCVD. Bridging the gap between evidence and practice requires not only innovative therapies but also systemic efforts to address cost barriers, enhance patient adherence, and expand accessibility. Emerging innovations like inclisiran and antisense oligonucleotides go beyond LDL-C reduction, tackling residual risk factors such as elevated lipoprotein(a) [Lp(a)] that remain inadequately addressed by conventional therapies [9, 10, 2].

By synthesizing evidence across diverse therapeutic modalities and patient populations, this work underscores the transformative potential of these therapies in redefining cardiovascular care. Aligning guideline recommendations with real-world findings provides clinicians with a comprehensive roadmap to optimize ASCVD management. Personalized treatment plans that incorporate advanced therapies tailored to individual risk profiles remain crucial for addressing the unmet need for more effective therapies [3, 7, 11].

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

The authors would like to thank Texila American University University for providing the facilities and resources necessary to carry out this study.

References

[1]. Banach, M., Reiner, Ž., Surma, S., 2024. Recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: A position paper of the International Lipid Expert Panel (ILEP). *Drugs*, https://doi.org/10.1007/s40265-024-02105-5

[2]. Sucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R., 2024. Cholesterol-lowering strategies for cardiovascular disease prevention: The importance of intensive treatment and the simplification of medical therapy. *Journal of Clinical Medicine*, **13**(7), 1882. https://doi.org/10.3390/jcm13071882

[3]. Ray, K. K., Reeskamp, L. F., Laufs, U., Banach, M., Mach, F., et al., 2022. Combination lipid-lowering therapy as a first-line strategy in very high-risk patients. *European Heart Journal*, **43**(8), 830–833. https://doi.org/10.1093/eurheartj/ehab718

[4]. El Din Taha, H. S., Kandil, H., Badran, H. M., Farag, N., Khamis, H., Nasr, G., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M., 2024. Egyptian consensus statement on the role of

non-statin therapies for LDL cholesterol lowering in different patient risk categories. *The Egyptian Heart Journal*, **76**(1), 131. https://doi.org/10.1186/s43044-024-00562-7

[5]. Panattoni, G., Monzo, L., Gugliotta, M., Proietti, G., Tatangelo, M., et al., 2023. Optimal management of patients after acute coronary syndrome. *European Heart Journal Supplements*, **25**(Suppl C), C84–C89. https://doi.org/10.1093/eurheartjsupp/suad039

[6]. Tokgözoğlu, L., & Libby, P., 2022. The dawn of a new era of targeted lipid-lowering therapies. *European Heart Journal*, **43**(34), 3198–3208. https://doi.org/10.1093/eurheartj/ehab841

[7]. Cannon, C. P., Khan, I., Klimchak, A. C., Reynolds, M. R., Sanchez, R. J., & Sasiela, W. J., 2017. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. *JAMA Cardiology*, **2**(9), 959–966. https://doi.org/10.1001/jamacardio.2017.2289

[8]. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., et al., 2019. 2018 AHA/ACC guideline on the management of blood cholesterol: Executive summary. *Journal of the American College of Cardiology*, **73**(24), 3168–3209. https://doi.org/10.1016/j.jacc.2018.11.002

[9]. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., et al., ESC Scientific Document Group. 2020. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *European Heart Journal*, **41**(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455

[10]. Schubert, J., Leosdottir, M., Lindahl, B., Westerbergh, J., Melhus, H., et al., 2024. Intensive early and sustained lowering of non-HDL cholesterol after myocardial infarction and prognosis: The SWEDEHEART registry. *European Heart Journal*, **45**(39), 4204–4215. https://doi.org/10.1093/eurheartj/ehae576

[11]. Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., et al., 2021. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study. *European Journal of Preventive Cardiology*, **28**(11), 1279–1289. https://doi.org/10.1093/eurjpc/zwaa047

[12]. Visseren, F. L. J., Mach, F., Smulders, Y. M., et al., 2021. ESC guidelines on cardiovascular disease prevention in clinical practice. *European Heart Journal*. https://doi.org/10.1093/eurheartj/ehab484

[13]. Marx, N., Federici, M., Schütt, K., et al., 2023. ESC guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). *European Heart Journal*, **44**(39), 4043–4140. https://doi.org/10.1093/EURHEARTJ/EHAD192

[14]. Newman, C. B., Preiss, D., Tobert, J. A., et al., 2019. Statin safety and associated adverse events: A scientific statement from the American Heart Association. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **39**(2), e38–e81. https://doi.org/10.1161/ATV.0000000000000073

[15]. Xie, C., Zhou, Z. S., Li, N., Bian, Y., Wang, Y. J., Wang, L. J., Li, B. L., & Song, B. L., 2012. Ezetimibe blocks the internalization of NPC1L1 and cholesterol in the mouse small intestine. *Journal of Lipid Research*, **53**(10), 2092–2101. https://doi.org/10.1194/jlr.M027359

[16]. Murphy, S. A., Cannon, C. P., Blazing, M. A., et al., 2016. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: The IMPROVE-IT trial. *Journal of the American College of Cardiology*, **67**(4), 353–361.

[17]. Roth, E. M., & Davidson, M. H., 2018. PCSK9 inhibitors: Mechanism of action, efficacy, and safety. *Review of Cardiovascular Medicine*, **19**.

[18]. Sabatine, M. S., Giugliano, R. P., Keech, A. C., et al., 2017. Evolocumab and clinical outcomes in patients with cardiovascular disease. *New England Journal of Medicine*, **376**(18), 1713–1722.

[19]. Schwartz, G. G., Steg, P. G., Szarek, M., et al., 2018. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *New England Journal of Medicine*, **379**(22), 2097–2107.

[20]. Wright, R. S., Ray, K. K., Raal, F. J., et al., 2021. Pooled patient-level analysis of inclisiran

trials in patients with familial hypercholesterolemia or atherosclerosis. *Journal of the American College of Cardiology*, **77**(9), 1182–1193.https://doi.org/10.1016/j.jacc.2020.12.058

[21]. Albosta, M. S., Grant, J. K., Taub, P., Blumenthal, R. S., Martin, S. S., & Michos, E. D., 2023. Inclisiran: A new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. *Vascular Health and Risk Management*, **19**, 421–431. https://doi.org/10.2147/VHRM.S338424

[22]. Bempedoic acid and ezetimibe combination approved by FDA for lowering LDL-C. 2024. *HCPLive*. Accessed August 18, 2024. Retrieved from https://www.hcplive.com/view/nexlizet-bempec-acid-ezetimibe-combination-approved-fda-cholesterol-esperion

[23]. Cho, L., 2023. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients at high cardiovascular risk: CLEAR outcome. *Journal of Clinical Lipidology*, **17**(4), e62.

[24]. Danis, R. P., Gangaputra, S., Hubbard, L., et al., 2010. Effects of medical therapies on retinopathy progression in type 2 diabetes. *New England Journal of Medicine*, **363**(3), 233–244. https://doi.org/10.1056/NEJMOA1001288

[25]. Lent-Schochet, D., & Jialal, I., 2023. Antilipemic agent bile acid sequestrants. *Stat Pearls*. Published January 23, 2023. Accessed April 2, 2024. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK549906/

[26]. Raal, F. J., Rosenson, R. S., Reeskamp, L. F., et al., 2020. Evinacumab for homozygous familial hypercholesterolemia. *New England Journal of Medicine*, **383**(8), 711–720. https://doi.org/10.1056/NEJMOA2004215

[27]. Blom, D. J., Raal, F. J., Santos, R. D., & Marais, A. D., 2019. Lomitapide and mipomersen: Inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis. *Current Atherosclerosis Reports*, **21**(12), 1–10. https://doi.org/10.1007/S11883-019-0809-3

[28]. Nugent, A. K., Gray, J. V., Gorby, L. K., & Moriarty, P. M., 2020. Lipoprotein apheresis: First FDA-indicated treatment for elevated lipoprotein (a). *Journal of Clinical Cardiology*, **1**(1), 16–21.